gastadj | R Documentation |
This meta-analysis was carried out by the GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research international Collaboration) group, using individual data on patients with curatively resected gastric cancer. Data from all published randomized trials, with a patient recruitment end date before 2004, and comparing adjuvant chemotherapy with surgery alone for resectable gastric cancers, were searched electronically. The candidate surrogate endpoint S was Desease-free survival time, defined as the time (in days) to relapse, second cancer or dead from any cause. The true endpoint T was the overall survival time, defined as the time (in days) from randomization to death of any cause or to the last follow-up.
data(gastadj)
This data frame contains the following columns:
The trial in which the patient was treated
The identification number of a patient
The treatment indicator, coded as 0 = Control and 1 = Experimental
The candidate surrogate (progression-free survival in days)
Censoring indicator for for Progression-free survival (0 = alive and progression-free, 1 = with progression or dead)
The true endpoint (overall survival time in days)
Censoring indicator for survival time (0 = alive, 1 = dead)
Oba K, Paoletti X, Alberts S, Bang YJ, Benedetti J, Bleiberg H, Catalona P, Lordick F, Michiels S, Morita A, Okashi Y, Pignon JP, Rougier P, Sasako M, Sakamoto J, Sargent D, Shitara K, Van Cutsem E, Buyse M, Burzykowski T on behalf of the GASTRIC group (2013). Disease-Free Survival as a Surrogate for Overall Survival in Adjuvant Trials of Gastric Cancer: A Meta-Analysis. JNCI: Journal of the National Cancer Institute;105(21):1600-1607
Add the following code to your website.
For more information on customizing the embed code, read Embedding Snippets.